Dose Ranging and Dose Frequency of LIPO-102
NCT00918814
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
DRUG:
LIPO-102
DRUG:
Placebo
Sponsor
Neothetics, Inc